Particulate Matter Exposure Aggravates IL-17-Induced Eye and Nose Inflammation in an OVA/Poly(I:C) Mouse Model

Jun-Sang Bae,†,2,3* Soo Bin Oh,†,4,5† Jeongyun Kim,†,6 Hoon Kim,†,4 Ji Hye Kim,†,1,2 Eun-Hee Kim,†,1,2 Kyong Jin Cho,†,4* Ji-Hun Mo,†,1,2,3*

1Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan, Korea
2Beckman Laser Institute Korea, Dankook University, Cheonan, Korea
3Medical Laser Research Center, Dankook University, Cheonan, Korea
4Department of Ophthalmology, College of Medicine, Dankook University, Cheonan, Korea
5Catholic Institute for Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea
6Department of Physics, College of Natural Sciences, Dankook University, Cheonan, Korea

ABSTRACT

Purpose: Data on the effects of direct particulate matter (PM) exposure on the eyes and the nose are limited. Here, an interleukin (IL)-17/neutrophil-dominant ovalbumin (OVA)/polyinosinic-polycytidylic acid (Poly(I:C)) mouse model was used to evaluate the effect of different-sized titanium dioxide (TiO₂) particles on the eyes and the nose. We also examined whether IL-17-neutralizing antibody (IL-17Ab) treatment could reverse TiO₂ effects.

Methods: The nasal cavities and conjunctival sacs of each mouse were challenged with OVA and Poly(I:C) to induce neutrophil-dominant inflammation and then exposed to micro- and nano-TiO₂. Subsequently, IL-17Ab was administered to investigate the role of IL-17 and inflammatory parameters.

Results: Micro- and nano-TiO₂ resulted in significant decreases in tear-break-up time and increases in corneal damage. Airborne micro-TiO₂ also increased nasal rubbing and sneezing counts compared with the OVA/Poly(I:C). Micro-TiO₂ exposure increased infiltration of neutrophils and IL-17A+ cells in the conjunctival tissues and the nasal mucosae. In addition, these increased symptoms and inflammation in the eyes and the nose by micro-TiO₂ exposure were inhibited by the IL-17Ab, suggesting IL-17 dependency.

Conclusions: TiO₂ aggravated IL-17-induced eye and nose inflammation and the IL-17Ab alleviated inflammation in the OVA/Poly(I:C) mouse model. These results may help develop a therapeutic modality for PM exposure and provide evidence for PM-associated diseases.

Keywords: Particulate matter; rhinitis; interleukin-17, conjunctivitis

INTRODUCTION

Air pollution induces various adverse health effects, including acute and chronic diseases of various organ systems. Furthermore, particulate matters (PMs), a complex mixture of solid and liquid particles suspended in air, are known to be the main contributor of air pollution.¹² The accumulation of PM might pose different health risks, depending on the
There are no financial or other issues that might lead to conflict of interest.

Disclosure

PM Aggravates Eye and Nose Inflammation

So Bin Oh
https://orcid.org/0000-0002-5150-5039
Jeongyun Kim
https://orcid.org/0000-0003-4085-5444
Hoon Kim
https://orcid.org/0000-0002-7932-1880
Ji Hye Kim
https://orcid.org/0000-0003-2516-774X
Eun-Hee Kim
https://orcid.org/0000-0002-9539-992X
Kyong Jin Cho
https://orcid.org/0000-0003-1468-467X
Ji-Hun Mo
https://orcid.org/0000-0003-1331-364X

Size and exposure route to the body. PMs enter the body through the following 3 main routes: inhalation via the respiratory system, ingestion via the digestive system, and absorption via the integumentary system. They are responsible for increased acute and chronic respiratory symptoms, cardiovascular conditions, and other related allergic reactions, resulting in more hospital admissions and emergency room visits.

Among the health risks, acute and chronic diseases in the eyes and the nose, such as conjunctivitis and rhinitis, are the most common. They are both known to have inflammatory symptoms and be caused by different kinds of environmental factors. Recent studies suggested that PM could be a major factor exacerbating the inflammation in both conjunctivitis and rhinitis, triggering inflammatory responses involving numerous cytokines and chemokines. Particularly, the cytokine interleukin-17 (IL-17) is known to be a strong inducer of inflammation in conjunctivitis and rhinitis.

Several studies have attempted to reveal the correlation between PM-related air pollution and various health issues based on clinical data. However, only a few in vivo studies have been conducted, and therefore, the direct effect of PM exposure on the eyes and nose and its underlying mechanisms need to be studied.

Titanium dioxide (TiO$_2$) is a metal oxide nanoparticle which usually used in commercial products such as paints, carpets, cosmetics, and textiles. Due to its small size, TiO$_2$ can cause damage to the eye surface, resulting in ocular inflammation. Symptoms include dryness, burning, itching, conjunctival injection, conjunctival chemosis, and swelling of eyelids. TiO$_2$ nanoparticles can also deposit to different parts of the respiratory system such as the nose and the lungs that causes inflammation.

In this study, the IL-17/neutrophil dominant ovalbumin (OVA)/polyinosinic-polycytidylic acid (Poly(I:C)) mouse model was used to evaluate the effect of different-sized TiO$_2$ on the mucosa of the eyes and the nose to confirm the role of IL-17 in the inflammatory process. In addition, we examined whether treatment with the IL-17-neutralizing antibody (IL-17Ab) could reverse the effect of TiO$_2$ on the eyes and nose.

MATERIALS AND METHODS

Protocol for mouse conjunctivitis and rhinitis model and exposure of TiO$_2$

To evaluate the effects of TiO$_2$ on the OVA/Poly(I:C) mouse model, 20 female BALB/c mice were divided into 4 groups.; 1) negative control group ((−) control), 2) positive control group (OVA/Poly(I:C)), 3) micro size TiO$_2$ + OVA/Poly(I:C) group (micro-TiO$_2$ + Poly(I:C)), and 4) nano size TiO$_2$ + OVA/Poly(I:C) group (nano-TiO$_2$ + Poly(I:C)) (Fig. 1A). Mice with positive control and TiO$_2$ + OVA/Poly(I:C) groups were locally sensitized with OVA (3.75 mg/mL)/Poly(I:C) (2.5 mg/mL) mixture in the conjunctival sac/or intranasally (20 μL) on day 1, 2, 3, 7 and 14. For the challenge, OVA (5 mg/mL, 20 μL/mouse) was administered into the same route from day 15 to day 20. In case of the micro size TiO$_2$ + OVA/Poly(I:C) group, the mice were exposed to micro-sized airborne TiO$_2$ (particulate matter less than 10 μm [PM$_{10}$], 600–700 μg/m$^3$) in a TiO$_2$ exposure chamber for 2 hours from day 14 to 20 (about 50 μg/m$^3$ based on 24 hours), which is similar to the short-term (24-hour) limit value (50 μg/m$^3$) of the Air Quality Guidelines set forth by the WHO for PM$_{10}$. Nano size TiO$_2$ (50 μg/mL, 20 μL/mouse/day) was administered into the conjunctival sac or the nasal cavity from day
PM Aggravates Eye and Nose Inflammation

14 to 20. Mice were sacrificed via cervical dislocation on day 21. The Dankook University Institutional Animal Care & Use Committee on the use and care of animal approved all animal experiments (DKU-17-021). All animal experiments were repeated 3 times, and the number of mice in each group was 5.

Fig. 1. The influences of exposed TiO$_2$ size on OVA/Poly(I:C) conjunctivitis mouse model. (A) Protocol for the induction of conjunctivitis and rhinitis with OVA/Poly(I:C) and micro or nano size TiO$_2$ in mice. (B) Tear-break-up time and tear volume measurements in all groups. (C) Corneal irregularities and corneal fluorescein staining images with corneal staining scores. (D) Histological staining for IL-17A-producing cells, conjunctival neutrophil, and conjunctival eosinophil. IL-17A producing cell counts (× 400 magnification, IHC with IL-17A antibody). Conjunctival neutrophil counts (× 400 magnification, IHC with NIMP-R14 antibody). Conjunctival eosinophil counts (× 400 magnification, IHC with hematoxylin and eosin staining). TiO$_2$, titanium dioxide; OVA, ovalbumin; Poly(I:C), polyinosinic-polycytidylic acid; IL, interleukin; IHC, immunohistochemistry; PBS, phosphate buffered saline. *P < 0.05.
Treatment of IL-17 neutralization antibody

An OVA/Poly(I:C) animal model and airborne micro size TiO$_2$ treatment were the same as in Fig. 1A, except that only airborne micro size TiO$_2$ treatment group and IL-17 neutralization antibody treatment group were added (n = 5/group). The micro TiO$_2$ group treated only airborne micro size TiO$_2$ without OVA/Poly(I:C) sensitization and OVA challenge, and IL-17 neutralization antibody administration was injected intraperitoneally for 7 days (day 14–20, 500 µg/mouse, 200 µL/mouse/day) in the same manner as OVA challenge and airborne micro size TiO$_2$ treatment.

TiO$_2$ exposure chamber

An exposure chamber with 6 fans was constructed for the exposure of TiO$_2$ particles on the ocular surface and nasal mucosa of mouse in this study. Titanium (IV) oxide, rutile, 99.5% (metal basis) with a mean diameter of 1.0 to 2.0 µm (Alfa Aesar; Johnson Matthey GmbH, Karlsruhe, Germany) was put in the exposure chamber, and airborne particle concentration in the exposure chambers was adjusted for PM$_{10}$ as measured by a MetOne 831 Aerosol Mass Monitor (Met One, Grants Pass, OR, USA). The range of airborne TiO$_2$ particle concentration during the study period was 600–700 µg/m$^3$.

Assessment of the ocular and nasal inflammation

The inflammation in the eyes were assessed by the standard tear break-up time (BUT) measurement, tear volume measurements, corneal irregularities, and corneal damage scores. Corneal damage was evaluated using Oxford schema, and the grades were marked as follows: 0, normal; 1–2, mild to moderate; and > 3, severe. The damages on the surface of the cornea were stained by the fluorescein dye and appeared green under the blue light.

For nasal symptoms, in a blind manner, the observer recorded the frequencies of sneezing and nasal rubbing for 15 minutes after the final OVA challenge.

Tissue preparations

Whole eyes of the mice were surgically excised and fixed in 4% formalin overnight. Next day, the eyes were transferred to 15% sucrose (Sigma-Aldrich, St. Louis, MO, USA) for 4 hours then, 30% sucrose overnight. They were embedded in Optimal Cutting Temperature (O.C.T.) compound (Tissue-Tek O.C.T. Compound; Sakura, Tokyo, Japan) for cryostat sectioning.

Half of the head was removed en bloc and fixed in 4% paraformaldehyde. The nasal mucosa was removed from the nasal cavity of the other half of the head using a small curette, immediately immersed in TRizol reagent (Invitrogen, Carlsbad, CA, USA), and stored at −80°C until use for reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

Eosinophils and cell aggregation in the conjunctival and nasal mucosa

Hematoxylin and eosin staining was performed to count the number of eosinophils in the conjunctival sac. The nasal septum histology was evaluated using standard Sirius red staining. The detailed procedure was described in our previous report.

Immunohistochemistry (IHC)

Prepared conjunctival and nasal mucosa sections were immunostained with NIMP-R14 (neutrophil marker, ab2557, 1:100; Abcam, Cambridge, MA, USA), IL-17 (LS-B4912, 1:100; LSBio, Seattle, WA, USA), IL-1β (ab9722, 1:200, Abcam), TNF-α (ab6671, 1:200; Abcam), CD4 (sc-13573, 1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), and B220 (B cell
marker, 14-0452-82, 1:50, eBioscience, San Diego, CA, USA) antibodies using Avidin-Biotinylated-Horseradish Peroxidase (HRP) Kits (Vector Laboratories, Burlingame, CA, USA). The detailed procedure was described in our previous report.

**Assay of IL-4, IL-17, and interferon (IFN)-γ levels in nasal mucosa**

Total RNA was prepared from nasal mucosa using TRizol reagent (Invitrogen). cDNA was synthesized from 1 μg of RNA using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). For analysis of IL-4 (Mm00445258_g1), IL-17 (Mm00439618_m1), IFN-γ (Mm99999071_m1), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Mm03302249_g1), pre-developed assay reagent kits were used (Applied Biosystems, Foster City, CA, USA). Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed on the ABI 7500 Real-Time PCR System (Applied Biosystems). Mean transcript levels were normalized to that of GAPDH.

**Serum levels of total IgE and OVA-specific IgE, IgG1, and IgG2a**

The serum levels of total and OVA-specific IgE, IgG1, and IgG2a were measured by solid-phase enzyme-linked immunosorbent assay. The detailed procedure was described in our previous report.

**Statistical analysis**

Statistical analysis was performed using SPSS software version 22.0 (SPSS Inc., Chicago, IL, USA). Data were tested using the Kruskal-Wallis test with Dunn multiple comparison test. A P value < 0.05 was considered as statistically significant.

**RESULTS**

**Effect of TiO₂ exposure on the OVA/Poly(I:C) conjunctivitis and rhinitis mouse models**

OVA/Poly(I:C)-induced mouse models were exposed to TiO₂ of different sizes to investigate its size-dependent effects in the conjunctival sac and nasal cavity.

As a result, tear BUT decreased in all case groups, compared to the (−) control. Nano-TiO₂ + Poly(I:C) group had the shortest BUT, followed by micro-TiO₂ + Poly(I:C) and Poly(I:C) groups, indicating that the size of TiO₂ affected BUT (Fig. 1B). Tear volume measurement showed that Poly(I:C) and TiO₂-exposed groups had more amount of tear than control group, as a symptom of eye irritation. Although micro-TiO₂ + Poly(I:C) group had the lowest tear volume, there were no significant differences among all groups (Fig. 1B).

White ring irregularities on corneal surface were observed in all the groups except the (−) control (Fig. 1C). The degree of irregularity was more severe in nano-TiO₂ + OVA/Poly(I:C) group, followed by Poly(I:C) and micro-TiO₂ + OVA/Poly(I:C) groups, indicating that nano-TiO₂ caused more damage on the corneal surface than micro-TiO₂. In addition, corneal fluorescein staining, which represents corneal damage, showed more damage in both micro-TiO₂ + Poly(I:C) and nano-TiO₂ + Poly(I:C) group, however, there was no statistically significant difference between micro-TiO₂ + Poly(I:C) and nano-TiO₂ + Poly(I:C) groups (Fig. 1C).

IHC showed that the level of IL-17A, neutrophil, and eosinophil increased in Poly(I:C) and TiO₂-exposed groups (Fig. 1D). Especially, IL-17A and neutrophil level increased significantly.
in micro-TiO$_2$ + Poly(I:C) group, indicating that micro-TiO$_2$ induced IL-17 and neutrophil related inflammatory process.

The nasal symptom score was significantly higher in the micro-TiO$_2$ + OVA/Poly(I:C) group than in the (−) control and nano-TiO$_2$ + OVA/Poly(I:C) groups (Fig. 2A). IL-17A mRNA expression was significantly higher in the micro-TiO$_2$ + OVA/Poly(I:C) group than in the

Fig. 2. The influences of exposed TiO$_2$ size on OVA/Poly(I:C) rhinitis mouse model. (A) Symptom score, frequencies of sneezing and nasal rubbing after the final OVA challenge. (B) Cytokine production in the nasal mucosa, mRNA expression (IL-4, IL-17A, and IFN-γ). (C) Histological staining for IL-17A-producing cells and inflammatory cells in the nasal mucosa. IL-17A producing cell counts (× 400 magnification, IHC with IL-17A antibody). Neutrophil counts (× 400 magnification, IHC with NIMP-R14 antibody). Eosinophil counts (× 400 magnification, Sirius red staining).

TiO$_2$, titanium dioxide; OVA, ovalbumin; Poly(I:C), polyinosinic-polycytidylic acid; IL, interleukin; IFN, interferon; IHC, immunohistochemistry. *P < 0.05; **P < 0.01; ***P < 0.001.
OVA/Poly(I:C) and nano-TiO₂+OVA/Poly(I:C) groups, as determined by the qPCR (Fig. 2B). However, the IL-4, IL-17A, and IFN-γ mRNA expression in the group exposed to nano-TiO₂ was not statistically significant compared with that in the OVA/Poly(I:C) group (Fig. 2B).

Nasal mucosal histological changes were assessed by IHC and Sirius Red staining for IL-17A-producing cell infiltration, neutrophils, eosinophils, and cell aggregation (Fig. 2C and Supplementary Fig. S1E). Intense aggregation of inflammatory cells under nasal mucosa epithelial tissue was defined as cell aggregation and evaluated by Sirius Red staining. The group treated with only OVA/Poly(I:C) had the higher numbers of IL-17A-producing cells, neutrophils, eosinophils, and cell aggregation in the nasal mucosa than the (−) control group. Meanwhile, in the nasal mucosa of groups exposed to TiO₂, the counts of eosinophils and cell aggregation were not significantly increased compared with those of the OVA/Poly(I:C) group. However, the IHC results revealed that the number of IL-17A-producing cells and neutrophils in the micro-TiO₂ group was statistically higher than that in the OVA/Poly(I:C) and nano-TiO₂ + OVA/Poly(I:C) groups. However, micro- and nano-TiO₂ were found to have no effect on serum total immunoglobulin (Ig)E, OVA-specific IgE, and IgG (Supplementary Fig. S1A).

The results of the influence of TiO₂ size revealed that IL-17A-expressing cells, neutrophils, and IL-17A mRNA levels were significantly higher in the nasal mucosa of mice exposed to airborne micro-TiO₂ than OVA/Poly(I:C) and nano-TiO₂. This is an additional effect of airborne micro-TiO₂ on the OVA/Poly(I:C) mouse model. On the contrary, nano-TiO₂ did not induce significant immunological and histological changes in the OVA/Poly(I:C) mouse model.

**Effect of IL-17Ab in OVA/Poly(I:C) conjunctivitis and rhinitis mouse models with micro-sized TiO₂ airborne exposure**

When the effects of micro- and nano-TiO₂ were compared, it was confirmed that micro size TiO₂ had a significant effect in IL-17 related inflammation both on the eyes and nose. To verify the role of IL-17 in the process, IL-17Abs were treated on the micro-TiO₂ + Poly(I:C) group.

Animal experiments with IL-17Ab were performed to investigate whether increased inflammatory response of nasal mucosa mediated by IL-17A and neutrophils is alleviated in the OVA/Poly(I:C) mouse model after exposure to micro-TiO₂ (Fig. 3A). BUT significantly increased in IL-17Ab + micro-TiO₂ + Poly(I:C) group when compared with micro-TiO₂ + Poly(I:C) group, indicating that the decreased BUT was recovered after IL-17 blocking antibody treatment (Fig. 3B). Poly(I:C) and IL-17Ab + micro-TiO₂ + Poly(I:C) groups had the lowest tear volume, with no significant differences. Tear volume in IL-17Ab + micro-TiO₂ + Poly(I:C) group was lower than micro-TiO₂ + Poly(I:C) group, implying the recovery of eye irritation (Fig. 3B).

Corneal irregularities were observed in Poly(I:C), micro-TiO₂, and micro-TiO₂ + Poly(I:C) groups, while IL-17Ab + micro-TiO₂ + Poly(I:C) group had a white ring image just as seen in (−) control group (Fig. 3C). Corneal fluorescein staining also showed the reduced green stains on corneal surface of IL-17Ab + micro-TiO₂ + Poly(I:C) group when compared with micro-TiO₂ + Poly(I:C) group, indicating a significant reduction in the damage after the IL-17 blocking antibody treatment (Fig. 3C). Although there were no significant differences of the corneal damage scores in all groups micro-TiO₂ + Poly(I:C) group were the most severe, and the corneal condition of IL-17Ab + micro-TiO₂ + Poly(I:C) group had even lower score than the negative control (Fig. 3C).
PM Aggravates Eye and Nose Inflammation

Fig. 3. The effects of IL-17Ab on the eyes of OVA/Poly(I:C) mouse model with micro size TiO₂ airborne exposure. (A) Protocol for the induction of conjunctivitis and rhinitis with OVA/Poly(I:C) and micro size TiO₂ in mice, with added IL-17Ab treatment group. (B) Tear break-up time and tear volume measurements in all groups. (C) Corneal irregularities and corneal fluorescein staining images with corneal damage scores. (D) Histological staining for IL-17A-producing cells, conjunctival neutrophil, and conjunctival eosinophil. IL-17A producing cell counts (× 400 magnification, IHC with IL-17A antibody). Conjunctival neutrophil counts (× 400 magnification, IHC with NIMP-R14 antibody). Conjunctival eosinophil counts (× 400 magnification, IHC with hematoxylin and eosin staining).

TiO₂, titanium dioxide; OVA, ovalbumin; Poly(I:C), polyinosinic-polycytidylic acid; IL, interleukin; IHC, immunohistochemistry; IL-17Ab, interleukin-17 neutralizing antibody.

*P < 0.05; **P < 0.01; ***P < 0.001.
IHC also confirmed that the inflammatory reaction was significantly increased in micro-TiO$_2$ and micro-TiO$_2$ + Poly(I:C) groups and decreased significantly in the IL-17Ab + micro-TiO$_2$ + Poly(I:C) group (Fig. 3D). The treatment of IL-17 blocking antibody significantly decreased the level of IL-17, neutrophil, and eosinophil, which was significantly increased with micro size TiO$_2$ exposure.

The symptom scores of nose scratching or sneezing after the last OVA challenge were the highest in the micro-TiO$_2$ + OVA/Poly(I:C)-treated group, which was significantly reduced by the IL-17Ab. The (−) control and micro-TiO$_2$ only groups showed similar symptom scores (Fig. 4A).

In mice treated with only micro-TiO$_2$, the levels of mRNA cytokines were relatively low similar to that of the (−) control group and IL-4 mRNA expression in the nasal mucosa was not different between the groups. The highest IL-17A mRNA expression in the group treated with micro-TiO$_2$ + OVA/Poly(I:C) was significantly reduced by the IL-17Ab treatment. However, the expression of mRNA IFN-γ was not statistically altered in the micro-TiO$_2$ + OVA/Poly(I:C) and IL-17Ab-treated groups compared with that in the OVA/Poly(I:C) group (Fig. 4B).

With regard to the histological changes of the nasal tissues (Fig. 4C), IL-17A-producing cells were the most abundant in the group treated with micro-TiO$_2$ + OVA/Poly(I:C), and this level decreased significantly in the IL-17Ab-treated group. The micro-TiO$_2$ + OVA/Poly(I:C) group was found to have the highest number of cell aggregation lesions, and its level was significantly decreased by IL-17Ab treatment. Similar to the number of IL-17A positive cells, the neutrophil count, which was significantly increased in the micro-TiO$_2$ + OVA/Poly(I:C) group compared with that in the OVA/Poly(I:C) group, was clearly reduced by IL-17Ab treatment. However, the number of eosinophils, B cells (B220$^+$ cells), and CD4 cells was similar in the OVA/Poly(I:C), micro-TiO$_2$ + OVA/Poly(I:C), and IL-17Ab treatment groups (Fig. 4C and Supplementary Fig. S1D). Cell aggregation was observed in the nasal mucosa epithelial tissue in the OVA/Poly(I:C) and micro-TiO$_2$ + OVA/Poly(I:C) groups by Sirius red staining (Supplementary Fig. S1E). The micro-TiO$_2$ + OVA/Poly(I:C) group was found to have the highest number of cell aggregation lesions, and its level was significantly decreased by IL-17Ab treatment. In the group treated with micro-TiO$_2$ only, there was negligible change in the nasal tissue compared with that in the (−) control group.

There was no statistically significant difference among the OVA/Poly(I:C), micro-TiO$_2$ + OVA/Poly(I:C), and IL-17Ab-treated groups in terms of total IgE, OVA-specific IgE, and IgG in the serum. The Ig level in the group treated with only TiO$_2$ was estimated to be similar to that of the (−) control group (Supplementary Fig. S1B).

The increase in the number of IL-17A positive cells and neutrophils in cell aggregates in OVA/Poly(I:C) mouse model exposed to micro-TiO$_2$ was significantly decreased by IL-17Ab. However, in all parameters examined, the group exposed to TiO$_2$ alone showed a similar pattern with the (−) control group.

**DISCUSSION**

Studies have reported that PMs cause respiratory and cardiovascular diseases and, in severe cases, even death.$^{5-25}$ Furthermore, PMs are known as a major cause of allergic conditions such as allergic conjunctivitis and allergic rhinitis, and the eyes and nose are the organs most
PM Aggravates Eye and Nose Inflammation

**Fig. 4.** The effects of IL-17Ab on the OVA/Poly(I:C) mouse model with micro size TiO$_2$ airborne exposure. (A) Symptom score, frequencies of sneezing and nasal rubbing after the final OVA challenge. (B) Cytokine production in the nasal mucosa, mRNA expression (IL-4, IL-17A, and IFN-γ). (C) Histological staining for IL-17A-producing cells and inflammatory cells in the nasal mucosa. IL-17A producing cell counts (×400 magnification, IHC with IL-17A antibody). Neutrophil counts (×400 magnification, IHC with NIMP-R14 antibody). Eosinophil counts (×400 magnification, Sirius red staining).

TiO$_2$, titanium dioxide; OVA, ovalbumin; IL, interleukin; IHC, immunohistochemistry; IFN, interferon; IL-17Ab, interleukin-17 neutralizing antibody.

*P < 0.05; **P < 0.01.
PM Aggravates Eye and Nose Inflammation

affected by PMs. To study the underlying mechanisms of these diseases, TiO$_2$ has been frequently used in *vivo* experiments as an effective approach to evaluate the effects of PMs in various cases.

In this study, we identified the relationship between micro- and nano-TiO$_2$ exposure and IL-17 inflammation in the eyes and nose of the OVA/Poly(I:C) mouse model. Poly(I:C) is a synthetic analogue of double-stranded RNA, recognized by Toll-like receptor 3 and mimics the replication intermediates present in RNA virus-infected cells. In a previous study, we developed an IL-17-dominant murine model of rhinitis via nasal instillation of OVA/Poly(I:C) associated with increased neutrophil counts. The OVA/Poly(I:C) mouse model had a lower Th-2 phenotype (eosinophil infiltration and Th-2 cytokine expression including IL-4 and IL-5) and a higher Th-17-associated inflammatory responses than the conventional OVA/alum model.

In general, depending on the size of the particle, the location of the particle in the airway is different. However, unlike the airways, in the eyes, especially the conjunctival sacs, it is difficult to remove the substances or particles introduced from the outside, regardless of the size, remaining in the closed conjunctival sacs. Therefore, it is thought that both micro- and nano-sized TiO$_2$ induce inflammation of the conjunctival tissues to a similar degree regardless of particle size in the eyes.

In the nasal cavity, the nose is the initial part of the airway and is connected to the lower respiratory tract, and when external substances enter the nasal passages, the particle’s size determines the particle’s location in the airway. It is known that most of the micrometer-sized particles remain in the nasal mucosa, but most of the nanometer-sized particles pass through the nasal passages and remain in the lungs. For this reason, micro-TiO$_2$ is thought to have a greater effect on the induction of inflammation in the nose than nano-TiO$_2$.

From the perspective of this experimental method, nano-TiO$_2$ was mixed with phosphate buffered saline (PBS) and treated by the intranasal route, and micro-TiO$_2$ was suspended in the chamber for a certain period of time and then exposed to mice. Compared with nano-TiO$_2$ mixed with PBS, micro-TiO$_2$ introduced in solid form could give more exposure to nasal mucosa.

This PM exposure has been shown to decrease BUT and increase tear volume as a symptom of eye irritation. When TiO$_2$ was administered to the eyes, inflammation and conjunctival hyperemia were observed and the frequency of blinking increased. BUT decrease and tear volume increase could be explained by corneal damage or imbalance in the tear film and increased blinking frequency, respectively. However, when the symptoms do occur, the tear film can be disrupted, reducing the amount of tears and eventually leading to dry eye.

IL-17, a cytokine related to T-cell activation and neutrophil mobilization and activation, is known to cause severe inflammatory diseases and maintain the condition by amplifying inflammation. The results showed that the number of IL-17-producing cells and neutrophils significantly increased in both the eyes and nose in the OVA/Poly(I:C) model after micro-size TiO$_2$ exposure. Wu et al. reported that micro-sized PM increased IL-17-secreting Th-17 cells and activated neutrophils to exacerbate allergic conditions, whereas nano-sized PM upregulated levels of IL-4 and IFN-γ in the respiratory system. As IL-17 and Th-17 cells are directly related to inflammatory diseases, they can be targeted to alleviate the disease symptoms.
A significant decrease in IL-17 and neutrophils was observed after IL-17Ab treatment, indicating that IL-17 plays a significant role in the symptoms of TiO$_2$-induced allergic inflammation. Some studies have suggested that anti-IL-17 therapies, such as IL-17 neutralization, might be effective in reversing destructive inflammation and treating inflammatory diseases.$^{35,38}$

In summary, this study is the first to our knowledge to compare and confirm the effects of PM exposure on both the eyes and nose using the OVA/Poly(I:C) mouse model. Micro–size PM had significant effects on the eyes and nose, resulting in IL-17 and neutrophil associated inflammation, and treatment with IL-17Ab reduced these levels of inflammation. This demonstrates that IL-17 regulation could play a key role in managing severe inflammatory symptoms in patients.

**ACKNOWLEDGMENTS**

This research was supported by Leading Foreign Research Institute Recruitment Program and Basic Science Research Program through the National Research Foundation through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (MSIT) (NRF-2018K1A4A302060572 and 2020R1A2C1012105), by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1A6A1A03043283) and by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health Welfare, Republic of Korea (HI20C2088). And this work was supported by the Technology Innovation Program (20016884, Development of a multiband Laser Patch devices with micro needle type optical transmission structure for symptom improvement of allergic rhinitis) funded By the Ministry of Trade, Industry & Energy (MOTIE, Korea).

**SUPPLEMENTARY MATERIAL**

**Supplementary Fig. S1**

The total and OVA specific immunoglobulin (IgE, IgG1, and IgG2a) levels of serum from rhinitis mouse model with micro or nano size TiO$_2$ (A) and the treatment of IL-17Ab with micro size TiO$_2$ (B) on the OVA/Poly(I:C) mouse model. (C) IHC on the conjunctival IL-1$\beta$ and TNF-$\alpha$ (× 400 magnification, IHC with IL-1$\beta$ and TNF-$\alpha$ antibodies respectively). (D) Nasal CD4 positive cell and B cell on the OVA/Poly(I:C) mouse model with IL-17Ab with micro size TiO$_2$ (× 400 magnification, IHC with CD4 or B220 antibodies respectively). (E) Histological staining for cell aggregation cells in the nasal mucosa of each mouse model. Number of cell aggregation (× 400 magnification, Sirius red staining).

Click here to view

**REFERENCES**

1. Goodkind AL, Tessum CW, Coggins JS, Hill JD, Marshall JD. Fine-scale damage estimates of particulate matter air pollution reveal opportunities for location-specific mitigation of emissions. Proc Natl Acad Sci U S A 2019;116:8775-80.

[PubMed](https://pubmed.ncbi.nlm.nih.gov/31502407/) | [Crossref](https://doi.org/10.1073/pnas.1920676116)
2. Adams K, Greenbaum DS, Shaikh R, van Erp AM, Russell AG. Particulate matter components, sources, and health: Systematic approaches to testing effects. J Air Waste Manag Assoc 2015;65:544-58.

3. Du Y, Gao B, Zhou H, Ju X, Hao H, Yin S. Health risk assessment of heavy metals in road dusts in urban parks of Beijing, China. Procedia Environ Sci 2013;18:299-309.

4. Hu X, Zhang Y, Ding Z, Wang T, Lian H, Sun Y, et al. Bioaccessibility and health risk of arsenic and heavy metals (Cd, Co, Cr, Cu, Ni, Pb, Zn and Mn) in TSP and PM2.5 in Nanjing, China. Atmos Environ 2012;57:146-52.

5. Kim KH, Kabir E, Kabir S. A review on the human health impact of airborne particulate matter. Environ Int 2015;74:136-43.

6. Wu JZ, Ge DD, Zhou LF, Hou LY, Zhou Y, Li QY. Effects of particulate matter on allergic respiratory diseases. Chronic Dis Transl Med 2018;4:95-102.

7. Mimura T, Ichinose T, Yamagami S, Fujishima H, Kamei Y, Goto M, et al. Airborne particulate matter (PM2.5) and the prevalence of allergic conjunctivitis in Japan. Sci Total Environ 2014;487:493-9.

8. Kang MH, Kim MK, Lee HJ, Lee HI, Wee WR, Lee JH. Interleukin-17 in various ocular surface inflammatory diseases. J Korean Med Sci 2011;26:938-44.

9. Bayrak Degirmenci P, Aksun S, Altin Z, Bilgir F, Arslan IB, Colak H, et al. Allergic rhinitis and its relationship with IL-10, IL-17, TGF-β, IFN-γ, IL-22, and IL-35. Dis Markers 2018;2018:9131432.

10. Roy D, Seo YC, Kim S, Oh J. Human health risks assessment for airborne PM10-bound metals in Seoul, Korea. Environ Sci Pollut Res Int 2019;26:24247-61.

11. Tang YJ, Chang HH, Chiang CY, Lai CY, Hsu MY, Wang KR, et al. A murine model of acute allergic conjunctivitis induced by continuous exposure to particulate matter 2.5. Invest Ophthalmol Vis Sci 2019;60:2118-26.

12. Li Y, Zhou J, Rui X, Zhou L, Mo X. PM2.5 exposure exacerbates allergic rhinitis in mice by increasing DNA methylation in the IFN-γ gene promoter in CD4+T cells via the ERK-DNMT pathway. Toxicol Lett 2019;301:98-107.

13. Baldacci S, Maio S, Cerrai S, Sarno G, Baiz N, Simoni M, et al. Allergy and asthma: effects of the exposure to particulate matter and biological allergens. Respir Med 2015;109:1089-104.

14. Stephen L. Titanium dioxide versatile solid crystalline: an overview. In: Dongre R, Peshwe DR. Assorted dimensional reconfigurable materials. London: IntechOpen; 2020.

15. Han JY, Kang B, Eom Y, Kim HM, Song JS. Comparing the effects of particulate matter on the ocular surfaces of normal eyes and a dry eye rat model. Cornea 2017;36:605-10.

16. Zhu S, Gong L, Li Y, Xu H, Gu Z, Zhao Y. Safety assessment of nanomaterials to eyes: an important but neglected issue. Adv Sci (Weinh) 2019;6:1802289.

17. Kwon S, Yang YS, Yang HS, Lee J, Kang MS, Lee BS, et al. Nasal and pulmonary toxicity of titanium dioxide nanoparticles in rats. Toxicol Res 2012;28:217-24.

18. Park EJ, Yoon J, Choi K, Yi J, Park K. Induction of chronic inflammation in mice treated with titanium dioxide nanoparticles by intratracheal instillation. Toxicology 2009;260:37-46.

19. World Health Organization. WHO air quality guidelines for particulate matter, ozone, nitrogen dioxide and sulfur dioxide: global update 2005: summary of risk assessment. Geneva: WHO; 2006.

20. Kaido M, Kawashima M, Ishida R, Tsubota K. Severe symptoms of short tear break-up time dry eye are associated with accommodative microfluctuations. Clin Ophthalmol 2017;11:861-9.
21. Yoon KC, Ahn KY, Choi W, Li Z, Choi IS, Lee SH, et al. Tear production and ocular surface changes in experimental dry eye after elimination of desiccating stress. Invest Ophthalmol Vis Sci 2011;52:7267-73.

22. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22:640-50.

23. Labbé A, Terry O, Brasnu E, Van Went C, Baudouin C. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea 2012;31:994-9.

24. Kim EH, Kim JH, Samivel R, Bae JS, Chung YJ, Chung PS, et al. Intralymphatic treatment of flagellin-ovalbumin mixture reduced allergic inflammation in murine model of allergic rhinitis. Allergy 2016;71:629-39.

25. Halonen JI, Lanki T, Yli-Tuomi T, Tiittanen P, Kulmala M, Pekkanen J. Particulate air pollution and acute cardiorespiratory hospital admissions and mortality among the elderly. Epidemiology 2009;20:143-53.

26. Kimura K, Sakamoto T, Miyazaki M, Uchino E, Kinukawa N, Isashiki M. Effects of volcanic ash on ocular symptoms: results of a 10-year survey on schoolchildren. Ophthalmology 2005;112:478-81.

27. Brozek JL, Bouquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol 2017;140:950-8.

28. Brook RD, Rajagopalan S, Pope CA 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, et al. Particulate air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation 2010;121:2331-78.

29. Chen EY, Garnica M, Wang YC, Chen CS, Chin WC. Mucin secretion induced by titanium dioxide nanoparticles. PLoS One 2011;6:e16198.

30. Stowell NC, Seideman J, Raymond HA, Smalley KA, Lamb RJ, Egenolf DD, et al. Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice. Respir Res 2009;10:43.

31. Bae JS, Kim EH, Kim JH, Mo JH. Mouse model of IL-17-dominant rhinitis using polyinosinic-polycytidylic acid. Allergy Asthma Immunol Res 2017;9:540-9.

32. Sager TM, Kommineni C, Castranova V. Pulmonary response to intratracheal instillation of ultrafine versus fine titanium dioxide: role of particle surface area. Part Fibre Toxicol 2008;5:17.

33. Shi H, Magaye R, Castranova V, Zhao J. Titanium dioxide nanoparticles: a review of current toxicological data. Part Fibre Toxicol 2013;10:15.

34. Löndahl J, Pagels J, Swietlicki E, Zhou J, Ketzel M, Massling A, et al. A set-up for field studies of respiratory tract deposition of fine and ultrafine particles in humans. J Aerosol Sci 2006;37:1152-63.

35. Zenobia C, Hajishengallis G. Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol 2000 2015;69:142-59.

36. Ogura H, Murakami M, Okuyama Y, Tsuruoka M, Kitabayashi C, Kanamoto M, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008;29:628-36.

37. Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflamm 2017;2017:3908061.

38. Song X, He X, Li X, Qian Y. The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity. Cell Mol Immunol 2016;13:418-31.